Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US-2017240585-A1 · Aug 24, 2017 · US
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US12281140B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12281140-B2 |
| Application number | US-202318143166-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 4, 2023 |
| Priority date | Nov 26, 2014 |
| Publication date | Apr 22, 2025 |
| Grant date | Apr 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a compound selected from the compounds below or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein said pharmaceutical composition is a solid dosage form suitable for oral administration. 2. The pharmaceutical composition according to claim 1 , which is a capsule or a tablet. 3. The pharmaceutical composition according to claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition according to claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition according to claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The pharmaceutical composition according to claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 7. The pharmaceutical composition according to claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition according to claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
spiro-condensed · CPC title
Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00 · CPC title
not condensed · CPC title
containing nitrile radicals, including thiocyanide radicals · CPC title
containing unsubstituted amino radicals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12281140B2 cover?
- The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
- Who is the assignee on this patent?
- Enanta Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J41/0055. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).